Rachel N. Grisham, Gopa Iyer, Karuna Garg, Deborah DeLair, David M. Hyman, Qin Zhou, Alexia Iasonos, Michael F. Berger, Fanny Dao, David R. Spriggs, Douglas A. Levine, Carol Aghajanian and David B. Solit BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer Cancer 119
Version of Record online: 28 AUG 2012 | DOI: 10.1002/cncr.27782
The valine-to-glutamate substitution at residue 600 (V600E) in BRAF mutation is present in 35% of serous borderline/low-grade serous ovarian cancers, and presence of the BRAF V600E mutation in these cancers is associated with early stage disease and an improved prognosis. Patients with serous borderline/low-grade serous cancers who require systemic therapy are unlikely to have tumors with BRAF mutations.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field